Tevogen Bio Holdings Inc.

Tevogen Bio is a clinical-stage specialty immunotherapy company focused on developing off-the-shelf, genetically unmodified precision T cell therapies. The company's mission is to address significant unmet medical needs in large patient populations across infectious diseases, cancers, and neurological disorders. Headquartered in Warren, New Jersey, Tevogen aims to make personalized T cell therapeutics affordable and accessible to a broad patient base.

Utilizing its proprietary ExacTcell platform, Tevogen harnesses the power of CD8+ cytotoxic T lymphocytes (CTLs) to develop its therapeutic pipeline. Key product candidates include TVGN 489, which has completed Phase 1 clinical trials for COVID-19 treatment and is being developed for Long COVID prevention. The company also has preclinical programs for TVGN 920 (cervical cancer), TVGN 960 (oropharyngeal cancer), TVGN 601 (multiple sclerosis), TVGN 930 (Epstein-Barr virus associated lymphomas), and TVGN 116 (hepatitis B). Additionally, Tevogen operates Tevogen.AI, an artificial intelligence initiative in partnership with Microsoft and Databricks, focused on accelerating drug discovery, optimizing clinical trials, and enhancing target detection. The company is also exploring strategic initiatives in healthcare services, generics, biosimilars, and medical devices.

Led by Co-Founder, CEO, and Chairperson Dr. Ryan Saadi, Tevogen Bio Holdings Inc. became publicly traded on NASDAQ under the ticker TVGN. The company recently expanded its corporate headquarters in Warren, New Jersey, centralizing its R&D and AI teams to enhance operational efficiency. Tevogen has been actively pursuing strategic acquisitions to support revenue growth, including evaluating a Management Services Organization (MSO) and a Contract Research Organization (CRO), and has announced the formation of a healthcare services initiative. The company also secured $3 million in PIPE financing and regained compliance with Nasdaq listing requirements.